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Abstract
Continuing cytotoxic chemotherapy is justiﬁed in metastatic breast cancer. However, the clinical effects of
successive treatment have not been evaluated. In the present study, we assessed 240 patients with metastatic
breast cancer who received multiple lines of cytotoxic chemotherapy regimens. We conﬁrmed that the
beneﬁcial effects of subsequent chemotherapy for patients with a durable response from previous treatment.
Background: We assessed the effect of chemotherapy regimens beyond ﬁrst-line agents on the clinical outcomes in
patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Patients
and Methods:We included 240 patients who were prospectively enrolled into various clinical trials and were receiving
cytotoxic chemotherapy for HER2-negative MBC at the National Cancer Center, Korea, from October 2002 to
September 2012. Clinicopathologic data were collected for the analysis. Results: A total of 240, 209, and 166 patients
received ﬁrst-, second-, and third-line chemotherapy, respectively. The median age was 49 years (range, 28-77 years),
and most had hormone receptor-positive cancer (n¼ 177; 73.8%). The median progression-free survival (PFS) was 7.6
months for ﬁrst-line (PFS1) versus 5.1 months for second-line (PFS2) versus 3.6 months for third-line (PFS3)
chemotherapy. The PFS from previous chemotherapy signiﬁcantly affected subsequent PFS: PFS1 for PFS2, PFS1
 7.6 months, hazard ratio (HR) 0.647; 95% conﬁdence interval (CI), 0.0.484-0.864 (P ¼ .003); PFS2 for PFS3, PFS2
 5.1 months, HR 0.676; 95% CI, 0.0.484-0.944; P ¼ .022). The median overall survival was 31.2 months (95% CI,
26.4-36.0 months). Hormone receptor positivity (HR 0.548; 95% CI, 0.261-0.499; P < .001) and PFS1  7.6 months
(HR 0.361; 95% CI, 0.393-0.765; P < .001) were signiﬁcant factors for survival on multivariate analysis. Conclusion:
The efﬁcacy of previous treatment signiﬁcantly affected the outcomes of subsequent treatment. We have conﬁrmed
that the succession of chemotherapy is justiﬁed in patients with MBC who beneﬁted from previous chemotherapy.
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The incidence and prevalence of breast cancer are increasing
globally. Although a greater proportion of women are diagnosed in
early disease stages because of national screening programs and
increasing awareness, 3% to 5% of patients still present with met-
astatic disease at diagnosis.1,2 In addition, 20% to 85% of patients
who undergo complete resection develop distant metastases.3
Metastatic breast cancer (MBC) is typically incurable, and one of
the important aims of treatment is symptom palliation. The median*This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).
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http://dx.doi.org/10.1016/j.clbc.2014.09.001survival of patients with MBC is 18 to 24 months.4 As under-
standing about cancer has broadened, several targeted therapies have
proved effective against MBC that has shown resistance to previous
chemotherapy regimens such as trastuzumab emtansine,5 lapatinib,6
and everolimus.7
Although randomized trials of some ﬁrst-line regimens have
shown improved survival and quality of life (QoL), few studies
have explored the effects of chemotherapy beyond ﬁrst-line
agents. Excluding hormonal therapy, anthracycline- and taxane-
containing regimens are considered the ﬁrst-line chemotherapy
agents for HER2 MBC.8,9 After tumors progress on these ﬁrst-
line regimens, other chemotherapeutic agents can be used, in-
cluding capecitabine, gemcitabine, vinorelbine, and cisplatin.
Although these drugs have been evaluated as second- or third-line
treatment,10-12 survival gain and preservation of QoL remain
debatable. Therefore, a systematic investigation of the beneﬁt of
chemotherapy beyond ﬁrst-line treatment has become necessary,
with the introduction of these more effective chemotherapeutic
drugs for the treatment of MBC.Clinical Breast Cancer February 2015 - e55
Table 1 Patient Characteristics (n [ 240)
Characteristic Median (Range) or Patients (%)
Age (years) 49 (28-77)
DFI (mo) 25.4 (0-246.4)
Patients with DFI
<2 years 118 (47.2)
2 years 132 (52.8)
De novo stage IV 57 (23.8)
ER/PgRþ/HER2 177 (73.8)
ER/PgR2/HER2 63 (26.3)
PS
0-1 199 (82.9)
2 19 (7.9)
Missing 22 (9.2)
Adjuvant chemotherapy
No 71 (29.6)
CMF 46 (19.2)
AC or FAC/FEC 54 (22.5)
AC-T 68 (28.3)
Other 1 (0.4)
Previous hormonal therapy
Adjuvant 165 (68.7)
Palliative 77 (32.1)
Visceral involvement
Yes 150 (62.5)
No 90 (37.5)
Abbreviations: AC ¼ doxorubicin, cyclophosphamide; CMF ¼ cyclophosphamide, methotrexate,
5-ﬂuorouracil; DFI ¼ disease-free interval; ER ¼ estrogen receptor; FAC ¼ 5-ﬂuorouracil,
doxorubicin, cyclophosphamide; FEC ¼ 5-ﬂuorouracil, epirubicin, cyclophosphamide; HER2 ¼
human epidermal growth factor receptor 2; PgR ¼ progesterone receptor; PS ¼ performance
status; T ¼ docetaxel or paclitaxel.
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e56 -In the present study, we assessed the effect of multiple chemo-
therapy regimens, speciﬁcally beyond the ﬁrst line, on the survival of
patients with HER2 MBC.
Patients and Methods
Study Population and Treatment
We included 240 patients who had received cytotoxic chemo-
therapy for MBC at the National Cancer Center, Korea, from
October 2002 to December 2012. All the patients had been pro-
spectively enrolled in various phase II and III clinical trials for
MBC. A total of 240, 209, and 166 patients received ﬁrst-, second-,
and third-line chemotherapy, respectively. The administered
chemotherapeutic regimens are listed in Supplemental Table 1
(available in the online version). A total of 48 patients (20%)
participated in > 2 clinical protocols subsequently after 1 regimen
had failed. Most patients had received chemotherapy until the
documentation of disease progression, unacceptable toxicity, or
patient and clinician decision.
Clinical data, such as performance status, age, and the presence of
visceral involvement, were collected at the initiation of the ﬁrst-line
chemotherapy for MBC. In addition, data on hormone receptor and
HER2 status, Ki-67 expression, and types of adjuvant systemic
treatment were collected for all patients from their medical records.
Patients with an initial diagnosis of metastatic disease were classiﬁed
as having de novo stage IV disease. In the present study, we deﬁned
hormone receptorepositive disease as > 10% of tumor cells with
estrogen receptor or progesterone receptor expression on immuno-
histochemical analysis.
Statistical Analysis
Five groups of chemotherapy were deﬁned according to the
principle agents used: anthracyclines, taxanes, capecitabine, gemci-
tabine or vinorelbine, and other drugs. The patients who received
combination regimens such as a taxane plus capecitabine or a taxane
plus anthracycline were arbitrarily assigned to the taxane group. The
Response Evaluation Criteria in Solid Tumors, version 1.0, was
used to assess the efﬁcacy for measurable or evaluable lesions using
the clinical or radiologic ﬁndings. The progression-free survival
(PFS) of patients receiving each drug was deﬁned as the interval
from the date of the ﬁrst administration of the speciﬁc drugs to the
date of the ﬁrst documented tumor progression or death from any
cause. Overall survival (OS) was deﬁned as the interval from the
date of the ﬁrst administration of the speciﬁc drugs to death from
any cause or the last follow-up date. PFS and OS were estimated
using the KaplaneMeier method and compared using the log-rank
test. Cox proportional hazards regression models were used to
control for various clinical factors and to estimate the hazard ratios
(HRs) and 95% conﬁdence intervals (CIs) for each factor.
Proportions were compared using 2-way tables and c2 tests. All
P values were 2 tailed, with 5% signiﬁcance levels. All statistical
analyses were performed using STATA, version 10.0.
Results
Patient Characteristics and Treatment Efﬁcacies
A total of 240 patients, with a median age of 49 years (range,
28-77 years) were analyzed. Most patients had hormone recep-
torepositive MBC (n ¼ 177, 73.8%), and 57 patients (23.8%)Clinical Breast Cancer February 2015were initially diagnosed as having de novo stage IV disease. The
median distant disease-free interval was 25.4 months (range,
0-246.4 months), and 150 patients (62.5%) had visceral metastasis
at diagnosis (Table 1). Of the 240 patients, 122 (50.8%) received
anthracycline-based and/or taxane-based adjuvant chemotherapy,
and 89 (50.3%) of those with hormone receptorepositive tumors
received palliative antihormonal therapy for metastatic disease.
The efﬁcacy stratiﬁed by the lines of chemotherapy in terms of
response and PFS is presented in Table 2. The most frequently
delivered chemotherapeutic regimens differed by the line of
chemotherapy. A total of 168 patients (70.0%) received taxane-
based chemotherapy as ﬁrst-line therapy; 85 (40.7%) received
capecitabine-containing regimens as second-line therapy; and 90
(54.2%) received gemcitabine- or vinorelbine-containing regimens
as third-line chemotherapy. The median PFS decreased with the
advancing lines of chemotherapy: 7.6 months for ﬁrst line (mPFS1)
versus 5.1 months for second line (mPFS2) versus 3.6 months
for third line (mPFS3). Although the objective response rates
to chemotherapy decreased with the increasing number of
lines (Table 2), the differences in the rates were statistically signif-
icant in the same lines, depending on the chemotherapeutic
regimen. As ﬁrst-line therapy, anthracycline-based chemotherapy
Table 2 Clinical Efﬁcacy of Chemotherapeutic Regimens in Each Line of Therapy
Regimen
First Line (n [ 240)
(mPFS1 7.6 mo; 95% CI 6.7-8.5)
Second Line (n [ 209)
(mPFS2 5.1 mo; 95% CI 4.3-5.9)
Third Line (n [ 166)
(mPFS3 3.6 mo; 95% CI 2.8-4.4)
PFS1 (mo) ORR1 (%) PFS2 (mo) ORR2 (%) PFS3 (mo) ORR3 (%)
Anthracycline based 8.6 (4.9-12.3) 26 (60.5) 5.2 (4.4-6.0) 18 (39.1) 3.1 (2.8-3.4) 1 (11.1)
Taxane based 7.7 (6.8-8.6) 91 (54.8) 6.3 (3.3-9.3) 24 (51.1) 2.4 (1.0-3.8) 1 (16.7)
Capecitabine based 5.7 (2.3-9.1) 10 (35.7) 5.8 (3.4-8.2) 33 (38.8) 5.5 (3.6-7.4) 20 (35.7)
Gemcitabine/
vinorelbine based
NA NA 4.0 (2.8-5.2) 6 (19.4) 3.0 (2.0-4.0) 11 (11.4)
P value .788 .105 .015 .048 .072 .196
Data in parentheses are 95% CIs, unless otherwise noted.
Abbreviations: CI ¼ conﬁdence interval; mPFS1 ¼ median progression-free survival of ﬁrst-line therapy; mPFS2 ¼ median progression-free survival of second-line therapy; mPFS3 ¼ median
progression-free survival of third-line therapy; NA ¼ not available; ORR ¼ objective response rate (complete response plus partial response).
In Hae Park et alshowed the highest response rate (60.5%). For second-line therapy,
a taxane-based regimen yielded the highest response rate (51.1%).
Finally, for third-line therapy, capecitabine-based chemotherapy
resulted in a 35.7% response rate. The responses to chemo-
therapy also differed by hormone receptor positivity (Figure 1).Figure 1 Effect of the Response of Chemotherapy According to the
Cancer. (B) HRL Breast Cancer Population
A
B
Abbreviations: CR ¼ complete response; PD ¼ progressive disease; PR ¼ partial response; SD ¼Moreover, the rate of primary resistance was much greater
in hormone receptorenegative cases (18.5% vs. 6.5%), and
resistance to chemotherapy emerged rapidly in this latter
population, which led to a lack of beneﬁt from subsequent therapy
(Figure 1B).Line of Therapy. (A) Hormone Receptor (HR)ePositive Breast
stable disease.
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e58 -Analysis of Factors Potentially Predictive of Survival
From Chemotherapy
On univariate analysis, hormone receptor positivity (HR 0.53;
95% CI, 0.43-0.78; P < .001), de novo stage IV disease (HR 0.64;
95% CI, 0.47-0.87; P ¼ .005), and the use of adjuvant chemo-
therapy (HR 1.19; 95% CI, 1.07-1.33; P ¼ .002) were signiﬁcantly
associated with the mPFS1 (Table 3). Of these factors, hormone
receptor positivity (HR 0.57; 95% CI, 0.42-0.76; P < .001)
remained as a signiﬁcant predictive factor for longer PFS1 on
multivariate analysis.
To investigate the effects of immediate previous drugs on sub-
sequent regimens, the patients were categorized according to the
mPFS duration for each line: those with a short duration of disease
control (less than the mPFS of each line) and those with prolonged
disease control (mPFS or longer for each line). In patients receiving
second-line therapy, a PFS1 > 7.6 months (HR 0.62; [95% CI,
0.47-0.83; P ¼ .001) was an important factor for longer PFS2,
along with hormone receptor positivity (Table 3). Similarly, PFS2
for > 5.1 months was a signiﬁcant factor for longer PFS3 in patients
receiving third-line therapy (HR 0.62; 95% CI, 0.44-0.85;
P ¼ .003).
The median OS was 2.6 years (95% CI, 2.2-3.0 years) and was
signiﬁcantly affected by hormone receptor status (positive vs.
negative, 3.4 years [95% CI, 3.0-3.8 years] vs. 1.7 years [95% CI,
1.3-2.1 years]). The response rates and PFS after ﬁrst-line therapy
were signiﬁcantly associated with OS. Figure 2 shows the survivalTable 3 Analysis for PFS in Each Line of Chemotherapy
Factor
Univariate Ana
HR (95% CI)
PFS1
De novo stage IV disease (yes vs. no) 0.64 (0.47-0.87)
Visceral disease (yes vs. no) 1.14 (0.87-1.50)
DFI (>2 years vs. 2 years) 1.00 (0.77-1.30)
Hormone receptor (þ vs. ) 0.53 (0.43-0.78)
Age (45 years vs. >45 years) 1.05 (0.80-1.37)
Adjuvant chemotherapy (yes vs. no) 1.19 (1.07-1.33)
PFS2
De novo stage IV disease (yes vs. no) 0.79 (0.57-1.11)
Visceral disease (yes vs. no) 1.05 (0.78-1.40)
DFI (>2 years vs. 2 years) 0.81 (0.61-1.08)
Hormone receptor (þ vs. ) 0.58 (0.42-0.80)
Age (45 years vs. >45 years) 1.07 (0.80-1.44)
Adjuvant chemotherapy (yes vs. no) 1.15 (1.02-1.29)
Median PFS1 7.6 mo 0.62 (0.47-0.83)
PFS3
De novo stage IV disease (yes vs. no)
DFI (>2 years vs. 2 years) 0.70 (0.50-0.96)
Hormone receptor (þ vs. ) 0.44 (0.31-0.64)
Adjuvant chemotherapy (yes vs. no) 1.17 (1.02-1.34)
Median PFS2 5.1 mo 0.62 (0.44-0.85)
Abbreviations: CI ¼ conﬁdential interval; DFI ¼ disease-free interval; HR ¼ hazard ratio; mPFS1 ¼ me
second-line therapy; mPFS3 ¼ median progression-free survival of third-line therapy; PFS ¼ progre
Clinical Breast Cancer February 2015difference according to the response and mPFS1 in both in hor-
mone receptorepositive and hormone receptorenegative breast
cancer. The factors for prolonged survival after the ﬁrst enrollment
were hormone receptorepositive disease (HR 0.57; 95% CI,
0.41-0.77; P ¼ .001), PFS1 longer than the median (7.6 months)
(HR 0.41; 95% CI, 0.29-0.56; P < .001), and an objective
response to ﬁrst-line therapy (HR 0.56; 95% CI, 0.41-0.77;
P < .001; Table 4).
Discussion
Although MBC can only rarely be cured, it can be managed
with effective treatment strategies. The therapeutic goals in this
setting are prolongation of survival and symptom control resulting
in good QoL. One population-based study revealed that new
therapeutic agents, including taxane, aromatase inhibitors, and
anti-HER2 therapy for MBC, have been associated with improved
survival.13 However, the aims of treatment can differ according to
multiple factors because MBC is a heterogeneous disease. These
factors include the speciﬁc tumor biology, the disease progression
rate, the presence of visceral metastases, a history of previous
therapy and the response, the toxicity of the therapeutic agents,
and patient preference. In the present study, we assessed the
clinical effects of subsequent chemotherapy after ﬁrst-line therapy.
We sought to identify the factors associated with the beneﬁts and
justiﬁcation of prolonged chemotherapy regimens. The clinical
beneﬁt of chemotherapy according to the PFS correlatedlysis Multivariate Analysis
P Value HR (95% CI) P Value
.005 0.74 (0.48-1.15) .177
.335
.976
<.001 0.55 (0.41-0.75) <.001
.748
.002 1.11 (0.95-1.30) .198
.171
.764
.147
.001 0.60 (0.44-0.82) .001
.641
.022 1.11 (0.99-1.25) .078
.001 0.65 (0.48-0.86) .003
.027 0.74 (0.53-1.05) .087
<.001 0.51 (0.35-0.73) <.001
.023 1.18 (1.03-1.35) .019
.003 0.68 (0.48-0.94) .022
dian progression-free survival of ﬁrst-line therapy; mPFS2 ¼ median progression-free survival of
ssion-free survival.
Figure 2 Overall Survival According to Response and Median Progression-Free Survival (mPFS) of First-Line Therapy in Both
Hormone Receptor (HR)ePositive and HRL Breast Cancer. (A) HRD (P < .001). (B) HRL (P < .001). (C) HRD (P < .001).
(D) HRL (P < .001)
Abbreviations: Cum ¼ cumulative; CR ¼ complete response; PD ¼ progressive disease; PR ¼ partial response; SD ¼ stable disease.
Table 4 Analysis for Clinical Factors Associated With Overall Survival in All Patients
Factor
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
mPFS1 (7.6 mo vs. <7.6 mo) 0.34 (0.25-0.46) <.001 0.41 (0.29-0.56) <.001
OR in ﬁrst therapy (yes vs. no) 0.43 (0.32-0.59) <.001 0.56 (0.41-0.77) <.001
DFI (>2 years vs. 2 years) 0.77 (0.57-1.04) .093 e e
Hormone receptor (þ vs. ) 0.48 (0.35-0.67) <.001 0.57 (0.41-0.80) .001
Age (45 years vs. >45 years) 1.16 (0.85-1.59) .345 e e
Visceral disease (yes vs. no) 0.99 (0.73-1.35) .969 e e
Adjuvant chemotherapy (yes vs. no) 1.23 (1.08-1.39) .001 1.60 (0.98-1.37) .079
De novo stage IV disease (yes vs. no) 0.35 (0.45-0.93) .018 1.07 (0.66-1.71) .793
Abbreviations: CI ¼ conﬁdence interval; DFI ¼ disease-free interval; HR ¼ hazard ratio; mPFS1 ¼ median progression-free survival of ﬁrst-line therapy; OR ¼ objective response (complete response
plus partial response); PFS ¼ progression-free survival.
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e60 -signiﬁcantly with the objective response rate, regardless of
hormone receptor status. Routinely, both anthracycline- and
taxane-based chemotherapy regimens have been recommended as
the initial therapy for MBC.8,14 In the present series, > 80% of
patients received anthracycline or a taxane as their ﬁrst-line
chemotherapy. Subsequently, capecitabine was used for the
second- or third-line therapy (see Supplemental Table 1 in the
online version). According to our data, the PFS with anthracycline-
or taxane-based chemotherapy was longer than that with
capecitabine-based therapy in the same line. All the patients who
received capecitabine as ﬁrst-line therapy had already been exposed
to anthracycline and/or taxane in an adjuvant or a neoadjuvant
setting and could have acquired resistance to multiple drugs.
Similarly, we could assume that patients with de novo stage IV
disease showed a signiﬁcantly prolonged PFS after ﬁrst-line treat-
ment compared with those who had received adjuvant or
neoadjuvant chemotherapy (Table 3).
In general, hormone receptorepositive disease has been regarded
as being less sensitive to cytotoxic chemotherapy than hormone
receptorenegative disease, which has been clearly demonstrated by
a lower pathologic complete response rate in the neoadjuvant
setting.15-17 However, we found that the PFS was signiﬁcantly
longer in those patients with hormone receptorepositive disease for
every line of treatment in the metastatic setting. These ﬁndings were
related to the greater disease control rate in the hormone
receptorepositive tumors than in the hormone receptorenegative
tumors (Figure 1). It is relevant that previous results for hormone
receptorenegative tumors showed a poor prognosis because of rapid
acquisition of drug resistance despite the initial responses.18-21
From our data, around 5% to 17% of patients developed primary
resistance to ﬁrst-line cytotoxic chemotherapy, and the proportion
of chemotherapy resistance increased by two- to threefold for the
subsequent line of therapy, regardless of hormone receptor posi-
tivity. Furthermore, the patients who had had no response to pre-
vious therapy showed a strong tendency for subsequent treatments
to fail. The phenomenon became more prominent with more
advanced lines of treatment (Figure 1). Therefore, the response to
previous treatment should be considered when making clinical
decisions to use more than third-line therapy.
Our cohort data showed that the PFS of ﬁrst-line therapy was
strongly associated with OS, consistent with previous results.22-24 In
addition, the response to the ﬁrst-line therapy and the presence of
hormone receptors were important prognostic factors for survival.
This information will be helpful for assessing the prognosis and as a
guideline in the treatment of patients with MBC. Every effort to
overcome resistance will be necessary for the patients who specif-
ically have primary resistance, including enrollment into clinical
trials with new targeted drugs.
The present study had several limitations. It was a retrospective
study that included patients who had been enrolled in various
clinical trials. Therefore, the chemotherapeutic regimens were
diverse, although all these regimens could be grouped by anthra-
cycline-, taxane-, or capecitabine-based combinations. In addition,
the present study did not assess the toxicity and QoL issues of the
treatment regimens. QoL is an important issue in the metastatic
setting, just as much as the treatment response and survival. For
these issues, prospective cohort studies are needed.Clinical Breast Cancer February 2015Conclusion
Successive chemotherapy is necessary for patients with MBC and
has been demonstrated to prolong OS and increase the QoL.
However, these effects from chemotherapy decreased with more
advanced lines of treatment. Patients with no response to a previous
line of therapy showed a strong tendency for subsequent treatment
to fail. Our results have shown that the PFS of ﬁrst-line therapy, the
response to the ﬁrst-line therapy, and the presence of hormone
receptors are important prognostic factors for survival and also
predictive factors for subsequent chemotherapy. Additional studies
should be focused to ﬁnd effective treatment regimens for those
patients with primary resistance to early lines of chemotherapy
regimens.
Clinical Practice Points
 Cytotoxic chemotherapies for patients with MBC have shown
improved survival and QoL.
 Around 5% to 17% of patients will develop primary resistance to
ﬁrst-line cytotoxic chemotherapy, and the proportion of
chemotherapy resistance increased by two- to threefold in the
subsequent line of therapy, regardless of hormone receptor
positivity.
 Patients who had no response to previous therapy showed a
strong tendency for failure with subsequent treatment regimens.
 The efﬁcacy of previous treatment signiﬁcantly affected the
outcomes of subsequent treatment.
 The PFS of ﬁrst-line therapy, the response to the ﬁrst-line
therapy, and the presence of hormone receptors were impor-
tant prognostic factors for survival and also were predictive
factors for subsequent chemotherapy.Acknowledgments
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Supplemental Table 1 Chemotherapeutic Regimens in Each
Line of Therapy
Regimen
Number of
Patients (%)
First-line therapy (n ¼ 240)
Anthracycline based 44 (18.3)
AC 7
FAC 33
FAC þ bevacizumab 4
Taxane based (D or P) 168 (70)
D 15
D þ capecitabine 25
D þ bevacizumab 1
P 72
P þ cisplatin 5
P þ gemcitabine 29
D þ doxorubicin 18
Ixabepilone þ capecitabine 3
Capecitabine based 28 (11.7)
Capecitabine þ irinotecan 8
Capecitabine þ bevacizumab 3
Capecitabine 14
S-1 þ oxaliplatin 3
Second-line therapy (n ¼ 209)
Anthracycline based 46 (22)
AC 3
FAC 43
Taxane based (D or P) 47 (22.5)
D 19
P 21
P þ cisplatin 1
Ixabepilone þ capecitabine 5
RPR109881A 1
Capecitabine based 85 (40.7)
Capecitabine þ irinotecan 28
Capecitabine 50
S-1 þ oxaliplatin 7
G and/or V 31 (14.8)
G 5
G þ cisplatin 7
G þ V 10
V 9
Third-line therapy (n ¼ 166)
Anthracycline based 9 (5.4)
AC 1
FAC 8
Taxane based 6 (3.6)
D 3
P 2
P þ cisplatin 1
Supplemental Table 1 Continued
Regimen
Number of
Patients (%)
Capecitabine based 56 (33.7)
Capecitabine þ irinotecan 14
Capecitabine 39
S-1 þ oxaliplatin 3
G and/or V 90 (54.2)
G 15
G þ cisplatin 41
G þ V 13
V 21
Other 5 (3.0)
Mitomycin C 4
Sunitinib 1
Abbreviations: AC ¼ doxorubicin plus cyclophosphamide; D ¼ docetaxel; FAC ¼ 5-ﬂuorouracil,
doxorubicin, cyclophosphamide; G ¼ gemcitabine; P ¼ paclitaxel; V ¼ vinorelbine.
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